What to Look For in an Online Semaglutide Program

Which semaglutide is the program actually prescribing?

Semaglutide products are not approved for the same things. Wegovy injection, with a reduced-calorie diet and more physical activity, is indicated to reduce excess body weight and maintain weight reduction long term in adults and in children aged 12 and older with obesity, and in adults with overweight plus at least one weight-related condition. It also carries indications for reducing major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight, and for treating noncirrhotic MASH with moderate to advanced fibrosis (F2 to F3) under accelerated approval [1]. Wegovy tablets were approved on 22 December 2025 for adults only [5][1].

Ozempic injection is a different label for a different purpose: glycemic control in type 2 diabetes, cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease, and reduced risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. Ozempic has no weight-loss indication [2]. Rybelsus and Ozempic tablets are approved for glycemic control and cardiovascular risk reduction in type 2 diabetes, and are not a weight-loss label [3].

The Wegovy label also states that Wegovy is not recommended in combination with other semaglutide-containing products or any other GLP-1 receptor agonist [1].

What FDA says about compounded semaglutide

Compounded drugs are not FDA approved, and FDA does not review them for safety, effectiveness or quality before they are marketed [4]. FDA says a product that is essentially a copy of an approved drug is allowed only if a prescriber documents a significant difference for the individual patient, or if it is made rarely: FDA does not intend to act against a compounder that fills four or fewer such prescriptions in a calendar month [6]. Adding an ingredient does not automatically change that: FDA says a product that combines semaglutide with vitamin B12 may still be essentially a copy if it is given the same way and the amounts of semaglutide and vitamin B12 are each within 10% of their respective commercial products [6]. On 30 April 2026 FDA proposed to exclude semaglutide, tirzepatide and liraglutide from the list of bulk substances outsourcing facilities may compound with, finding no clinical need; comments were due 29 June 2026 and FDA says no final decision has been made [7].

FDA also reports dosing errors with compounded injectable semaglutide, including patients measuring the wrong dose, clinicians miscalculating and doses above the label, and says semaglutide sodium and semaglutide acetate salts are different active ingredients from the approved drug with no lawful basis for use in compounding that the agency is aware of [4]. As of 31 May 2026 FDA had received 990 adverse event reports for compounded semaglutide and says the count likely undercounts [4].

What the labels say screening should cover

Semaglutide labels list these contraindications: a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and a prior serious hypersensitivity reaction to semaglutide or a product ingredient, with anaphylaxis and angioedema reported [1][2][3]. The boxed warning also directs prescribers to counsel patients on the symptoms of thyroid tumors, which include a mass in the neck, difficulty swallowing, shortness of breath and persistent hoarseness [1].

The labels also describe these situations that bear on a prescription:

• Pregnancy. The Wegovy label says weight loss offers no benefit in pregnancy and may cause fetal harm, and says to discontinue Wegovy when pregnancy is recognized if it is being used for weight reduction and to stop at least 2 months before a planned pregnancy because of the long half-life [1].
• Insulin or a sulfonylurea. The label says semaglutide with either raises hypoglycemia risk and that reducing the insulin or secretagogue dose may be necessary [1].
• Severe gastroparesis, in which semaglutide is not recommended [1].
• A history of diabetic retinopathy, which the label says patients should be monitored for [1].
• Prior kidney impairment, because acute kidney injury from volume depletion has been reported, more often in people with prior renal impairment and during dose escalation, usually after gastrointestinal fluid loss [1].

The label titration schedule

The Wegovy injection label starts at 0.25 mg weekly for weeks 1 to 4, then 0.5 mg for weeks 5 to 8, 1 mg for weeks 9 to 12, 1.7 mg for weeks 13 to 16, and maintenance from week 17 at 2.4 mg or 1.7 mg. Adults who tolerate 2.4 mg for at least 4 weeks and need more weight loss may go to a maximum of 7.2 mg weekly [1]. Missed doses have their own rule: give the dose if the next scheduled dose is more than 2 days away, and after two or more consecutive missed doses, re-escalate from a lower dose [1].

The Wegovy label says the tablets are taken daily on an empty stomach in the morning with up to 4 ounces of plain water, swallowed whole, with at least 30 minutes before food, drink or other oral medicines, and that a missed dose is skipped [1]. The Rybelsus and Ozempic tablets label gives the same routine and says the two products are not substitutable milligram for milligram [3].

The Ozempic and Rybelsus labels note that most reports of nausea, vomiting and diarrhea in their trials occurred during dose escalation [2][3]. A program that starts at a maintenance dose is not following the labeled Wegovy schedule above.

What follow-up has to cover

In pooled placebo-controlled trials of Wegovy 2.4 mg in adults with obesity or overweight, up to 68 weeks, nausea occurred in 44% versus 16% on placebo, diarrhea in 30% versus 16%, vomiting in 24% versus 6% and constipation in 24% versus 11%. Any gastrointestinal reaction occurred in 73% versus 47%, and 6.8% versus 3.2% discontinued for an adverse reaction [1]. Severe gastrointestinal reactions were reported in 4.1% versus 0.9% [1].

The label's other warnings include acute pancreatitis, with the label saying to discontinue if it is suspected; gallbladder disease, with cholelithiasis in 1.6% versus 0.7% and cholecystitis in 0.6% versus 0.2% in adult injection trials; hypoglycemia with insulin or a sulfonylurea; acute kidney injury from volume depletion; hypersensitivity reactions; diabetic retinopathy complications; a mean heart rate increase of 1 to 4 beats per minute; and pulmonary aspiration during general anesthesia or deep sedation [1]. The Ozempic label says its pens must never be shared between patients, even if the needle is changed [2].

Shipping, storage and what is in the box

FDA recommends that multi-dose vials of sterile medication be discarded 28 days after first use, even if medication remains, and says not to keep using a vial past that point even if the compounder's instructions say otherwise; a new sterile needle and syringe for each dose is also recommended [4]. FDA says injectable GLP-1 drugs require refrigeration, has received complaints that some compounded products arrived warm or with inadequate ice packs, and recommends not using an injectable GLP-1 that arrives warm or insufficiently refrigerated [4]. FDA also warns about counterfeit Ozempic [4].

FDA's own list of seller red flags

FDA publishes warning signs for telehealth sellers of GLP-1 drugs. They include sending medicine that looks different from what was pictured, or that arrives in damaged packaging or without instructions for use; providing medicine without screening and a prescription by a licensed doctor; not having a licensed doctor available to answer questions after the medication arrives; and labels with spelling errors, incorrect pharmacy addresses or a pharmacy name that may be fraudulent [4].

What to expect from the drug itself

In STEP 1, a weight-management trial, 1,961 adults without diabetes who had obesity, or overweight with at least one weight-related condition, were randomized to semaglutide 2.4 mg weekly or placebo for 68 weeks. Mean weight change was -14.9% versus -2.4%, and 86.4% versus 31.5% lost at least 5% of body weight [8].

In STEP 4, 803 adults who reached 2.4 mg after a 20-week run-in were randomized to continue semaglutide or switch to placebo; from week 20 to week 68, weight changed by -7.9% on continued semaglutide and +6.9% on placebo [9]. In an exploratory extension of 327 STEP 1 participants, semaglutide-treated participants regained 11.6 percentage points of lost weight in the year after treatment stopped, for a net loss of 5.6% from baseline at week 120 [10].